The submission is founded on a robust clinical advancement programme involving a lot more than 3.

AstraZeneca Announces European SEROQUEL XR Submission AstraZeneca has announced its submission of SEROQUEL XR to European regulatory authorities looking for acceptance for both short-term and maintenance treatment of Generalised PANIC . This is actually the first-time acceptance offers been sought in European countries for an atypical antipsychotic medication for the treating GAD http://cialishinta.com http://cialishinta.com . The submission is founded on a robust clinical advancement programme involving a lot more than 3,500 individuals in five Stage III efficacy and security studies. Data from the program were presented previous this season at the 21st ECNP Congress in Barcelona in September and at the 161st Annual Achieving of the American Psychiatric Association in Washington, D.C.

Other Posts From Category "immunology":

Related Posts